Page results
-
This page has been written for patients who are having radioactive iodine (131I) ablation and/or radioiodine treatment for thyroid cancer.
-
UCLH will be part of a major UK research study looking at the long-term health impacts of COVID-19.
-
Researchers at UCLH and UCL have completed the first and only randomised trial to explore a new approach to treating aggressive lung cancer.
-
Neurological complications of COVID-19 can include delirium, brain inflammation, stroke and nerve damage, finds a new UCL and UCLH-led study.
-
This page is for cancer patients receiving immunotherapy treatment.
-
Patients with COVID-19 will be given the cystic fibrosis drug ‘Dornase alfa’ to determine if it can help improve survival by reducing excess inflammation in the lungs in a trial at UCLH.
-
This information is for patients receiving steroids for immunotherapy toxicity.
-
UCLH has recruited the first patient to a global study of a new drug in early development, called NI0752, which is thought to reduce the production of a protein in the brain called tau.
-
Mixed sex accommodation and privacy information for patients coming into hospital for an inpatient stay
-
Specialist teams at UCLH and UCL are at the forefront of research which could bring hope to people who have been robbed of their sense of smell and taste after suffering the long-term legacy of COVID-19.
File results
-
FOI/2024/0577 - Diffuse Large B Cell Lymphoma treatments
-
FOI/2024/0578 - Public identity insurance policies held by Fertility Clinic that cover data breaches
-
FOI/2024/0580 - Newborns taken into care from the maternity wards 2019-2023
-
FOI/2024/0581 - Weight management services/ bariatric surgery/ access to Wegovy
-
FOI/2024/0582 - SACT (systemic anti-cancer therapy) treatments for endometrial cancer
-
FOI/2024/0587 - Colorectal cancer treatments
-
FOI/2024/0594 - Implementation of Federated Data Platform (FDP) and procurement of data platforms
-
FOI/2024/0589 - SACT Cancer report/ Drug Patient Level Contract Monitoring (DrPLCM) report
-
FOI/2024/0438 - IT electronic signature software service/ e-Signatures
-
FOI/2024/0586 - Subject Access Requests (SAR) and Freedom of Information (FOI) requests for 2023/24